Disclosed is an humanized anti-a2 integrin antibody comprising: (i) a heavy chain variable region comprising the amino acid sequence of (a) HCDR2 (VIWARGFTNYNSALMS, SEQ ID NO:2), (b) HCDR1 (GFSLTNYGIH, SEQ ID NO:1), HCDR2 (VIWARGFTNYNSALMS, SEQ ID NO:2) and HCDR3 (ANDGVYYAMDY, SEQ ID NO:3), or (c) SEQ ID NO:40； and (ii) a light chain variable region comprising the amino acid sequence of (a) an LCDR1 selected from SANSSVNYIH (SEQ ID NO:4) or SAQSSVNYIH (SEQ ID NO:112), (b) LCDR2 (DTSKLAS； SEQ ID NO:5) and (c) LCDR3 (QQWTTNPLT, SEQ ID NO:6). Also disclosed is an humanized anti-a2 integrin antibody, wherein the antibody binds an epitope of a2 integrin, the epitope comprising: (a) a Lys residue corresponding to position 192 of the a2 integrin amino acid sequence set forth in SEQ ID NO:8 or position 40 of the a2 integrin I domain amino acid sequence set forth in SEQ ID NO:11； (b) an Asn residue corresponding to position 225 of the a2 integrin amino acid sequence set forth in SEQ ID NO:8 or position 73 of the a2 integrin I domain amino acid sequence set forth in SEQ ID NO:11； (c) a Gln residue corresponding to position 241 of the a2 integrin amino acid sequence set forth in SEQ ID NO:8 or position 89 of the a2 integrin I domain amino acid sequence set forth in SEQ ID NO:11； (d) a Tyr residue corresponding to position 245 of the a2 integrin amino acid sequence set forth in SEQ ID NO:8 or position 93 of the a2 integrin I domain amino acid sequence set forth in SEQ ID NO:11； (e) an Arg residue corresponding to position 317 of the a2 integrin amino acid sequence set forth in SEQ ID NO:8 or position 165 of the a2 integrin I domain amino acid sequence set forth in SEQ ID NO:11； (f) an Asn residue corresponding to position 318 of the a2 integrin amino acid sequence set forth in SEQ ID NO:8 or position 166 of the a2 integrin I domain amino acid sequence set forth in SEQ ID NO:11； or (g) any combination of (a) to (f). Also disclosed is the use of the said anti-á2 integrin antibody
